Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need

Pivotal phase 2 DESTINY-Breast01 trial met primary endpoint, supporting global regulatory submission plan to start in first half of fiscal year 2019 TOKYO and MUNICH and BASKING RIDGE, N.J., May 8, 2019 -- (Healthcare Sales & Marketing Network) -- Daii... Biopharmaceuticals, Oncology Daiichi Sankyo, AstraZeneca, trastuzumab deruxtecan, breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news